Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will host a conference call and webcast on Tuesday, March 7, 2023, at 8:15 a.m. Eastern Time, to provide an update on its regulatory and partnering strategy for the United States and Europe. The company will also present and discuss the findings from its subgroup analysis of ONWARD data.

Adial Pharmaceuticals Schedules Business Update Conference Call

CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced at-the-market registered direct offering of 1,829,269 shares of common stock at a purchase price of $0.41 per share of common stock with a single institutional investor for gross proceeds of $0.75 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company.

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase $0.75 million of its common stock in an at-the-market registered direct offering.

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Buckle

Eastside Distilling

Insight Enterprises

Ruth's Hospitality Group

Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).

Forget Bargain Hunting: Play 5 Stocks With Rising P/E

PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain

PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model

Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate's PNV-6005 as a Potential Treatment for Ulcerative Colitis

Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher

Kevin Schuyler appointed Chairman of Adial's Board

Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer

Onward Phase III Clinical Trial of Adial Pharmaceutical's AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy drinking days, the primary end-points were not achieved in.

Adial Clinical Trial: A Fluff Or A Win?

Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder

Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Shares of small-cap penny stock Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares are trading about 20.5% lower at $1.46 per share Wednesday morning. The company announced topline results for its Onward Phase 3 trial for AD04 in patients with Alcohol Use Disorder.

What's Going On With Adial Pharmaceuticals Stock Today?

AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking

Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET

Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

Twin Vee PowerCats Co

FORT PIERCE, FL / ACCESSWIRE / July 7, 2022 / Twin Vee PowerCats Co. (Nasdaq:VEEE) ("Twin Vee" or the "Company"), a designer, manufacturer, distributor, and marketer of power sport catamaran boats, today announced that Kevin Schuyler was appointed to its Board of Directors on July 6, 2022. He replaces Steven Shallcross, who stepped down on June 30th.

Twin Vee PowerCats Co.'s Board of Directors Appoints Kevin Schuyler as Newest Director

CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders from the Company's CEO, William Stilley.

Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley

Expects Release of Top-Line Data in July Expects Release of Top-Line Data in July

Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial

New patent covers the use of the full genetic panel measuring all five genetic biomarkers New patent covers the use of the full genetic panel measuring all five genetic biomarkers

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company's Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, has entered into a research collaboration with the Medical College of Wisconsin, a leading medical school, and Dr. John Auchampach, PhD, Professor and Vice Chair of the Department of Pharmacology and Toxicology. The goal of the collaboration is to further evaluate the Company's proprietary adenosine analogs as potential treatments for diabetes and non-alcoholic steatohepatitis (NASH). NASH is the most severe form of non-alcoholic fatty liver disease involving liver inflammation (hepatitis) that can lead to life-threatening cardiovascular co-morbidities.

Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate's Adenosine Compounds as Potential Treatments for Diabetes and NASH

Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter

Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major unmet medical needs, has entered into a research collaboration agreement with the University of California San Diego (UC San Diego), a leading education and research university, and Dr. Peter Ernst, DVM, PhD, Professor of Pathology and an expert in the fields of immunology, inflammation and infectious disease, to further evaluate the Company's proprietary adenosine analogs as a potential treatment for inflammatory diseases, including inflammatory bowel disease (IBD) and infectious diseases where a large immune response (i.e., cytokine storm) plays a significant role.

Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate's Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders

Chico's FAS

G-III Apparel Group

TAL Education Group

Pilgrim's Pride

Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.

News for Adial Pharmaceuticals Inc Stock (ADIL)